Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Pharma Mar SA ( (ES:PHM) ) has provided an update.
Pharma Mar S.A., along with its partner Adium Pharma S.A., has received conditional marketing approval in Argentina for Zepzelca® (lurbinectedin) for the treatment of metastatic small cell lung cancer (SCLC). This approval, based on clinical trial data, expands the availability of lurbinectedin to 18 territories globally, reinforcing Pharma Mar’s position in the oncology market and providing a new treatment option for a particularly aggressive form of lung cancer.
The most recent analyst rating on (ES:PHM) stock is a Buy with a EUR108.00 price target. To see the full list of analyst forecasts on Pharma Mar SA stock, see the ES:PHM Stock Forecast page.
More about Pharma Mar SA
Pharma Mar S.A. operates in the pharmaceutical industry, focusing on the development and commercialization of oncology drugs. The company is known for its innovative treatments targeting various forms of cancer, with a significant market presence in both Europe and Latin America.
YTD Price Performance: -1.63%
Average Trading Volume: 59,625
Technical Sentiment Signal: Buy
Current Market Cap: €1.41B
For a thorough assessment of PHM stock, go to TipRanks’ Stock Analysis page.